Laboratory Co. of America Holdings (NYSE:LH - Get Free Report) EVP Der Vaart Sandra D. Van sold 1,314 shares of the stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $251.30, for a total value of $330,208.20. Following the transaction, the executive vice president now directly owns 2,171 shares in the company, valued at approximately $545,572.30. This represents a 37.70 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Laboratory Co. of America Price Performance
LH traded up $2.97 on Monday, reaching $254.01. The company had a trading volume of 727,806 shares, compared to its average volume of 583,570. The company has a market capitalization of $21.25 billion, a P/E ratio of 28.80, a PEG ratio of 1.71 and a beta of 1.07. The company has a current ratio of 1.44, a quick ratio of 1.30 and a debt-to-equity ratio of 0.67. The company has a fifty day moving average of $241.20 and a 200-day moving average of $232.78. Laboratory Co. of America Holdings has a one year low of $191.97 and a one year high of $258.59.
Laboratory Co. of America (NYSE:LH - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $3.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.40 by $0.05. Laboratory Co. of America had a net margin of 5.73% and a return on equity of 15.29%. As a group, equities research analysts anticipate that Laboratory Co. of America Holdings will post 16.01 earnings per share for the current year.
Laboratory Co. of America Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Wednesday, March 12th. Stockholders of record on Thursday, February 27th will be given a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 1.13%. The ex-dividend date of this dividend is Thursday, February 27th. Laboratory Co. of America's dividend payout ratio (DPR) is presently 32.65%.
Analysts Set New Price Targets
LH has been the subject of several research reports. Piper Sandler lifted their price target on shares of Laboratory Co. of America from $240.00 to $260.00 and gave the company a "neutral" rating in a report on Monday, February 10th. Barclays decreased their target price on Laboratory Co. of America from $271.00 to $260.00 and set an "equal weight" rating for the company in a research note on Friday, February 7th. StockNews.com raised Laboratory Co. of America from a "hold" rating to a "buy" rating in a report on Friday, February 7th. Jefferies Financial Group raised their price target on Laboratory Co. of America from $275.00 to $290.00 and gave the stock a "buy" rating in a report on Thursday, February 6th. Finally, Bank of America upped their price objective on Laboratory Co. of America from $262.00 to $271.00 and gave the stock a "buy" rating in a research note on Friday, December 13th. Three research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Laboratory Co. of America currently has an average rating of "Moderate Buy" and an average price target of $265.75.
View Our Latest Stock Report on Laboratory Co. of America
Institutional Trading of Laboratory Co. of America
Several institutional investors have recently modified their holdings of LH. AMF Tjanstepension AB lifted its holdings in Laboratory Co. of America by 37.0% in the 3rd quarter. AMF Tjanstepension AB now owns 86,026 shares of the medical research company's stock valued at $19,232,000 after acquiring an additional 23,221 shares during the last quarter. Private Advisor Group LLC lifted its stake in Laboratory Co. of America by 55.2% during the third quarter. Private Advisor Group LLC now owns 8,410 shares of the medical research company's stock valued at $1,879,000 after purchasing an additional 2,990 shares during the last quarter. International Assets Investment Management LLC lifted its stake in Laboratory Co. of America by 59,626.5% during the third quarter. International Assets Investment Management LLC now owns 67,491 shares of the medical research company's stock valued at $15,083,000 after purchasing an additional 67,378 shares during the last quarter. Assenagon Asset Management S.A. bought a new stake in Laboratory Co. of America during the third quarter worth approximately $854,000. Finally, Ballentine Partners LLC acquired a new position in Laboratory Co. of America in the third quarter worth approximately $249,000. Institutional investors and hedge funds own 95.94% of the company's stock.
Laboratory Co. of America Company Profile
(
Get Free Report)
Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.
See Also
Before you consider Laboratory Co. of America, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Laboratory Co. of America wasn't on the list.
While Laboratory Co. of America currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
